AI biomarker discovery that holds up in validation
Integrate multiomics and clinical evidence to build robust biomarker hypotheses validated across independent patient cohorts – ready for prospective trial validation.
Why promising biomarker signals fail before validation
A promising signal in one dataset is not yet a decision-ready biomarker. Biomarker programs often stall when fragmented data, cohort differences and limited biological context make it difficult to reproduce a finding outside the discovery cohort.
Ardigen provides AI biomarker discovery services that combine bioinformatics, multiomics data integration and cross-cohort evidence. The goal is not another ranked list of correlations. It is a defensible set of biomarker candidates with a clear validation strategy and traceable evidence behind every priority.
Discovery-only correlations
Statistically significant signals may disappear when tested in independent cohorts
Fragmented multiomics and clinical data
Genomics, transcriptomics, proteomics, single-cell, imaging and clinical outcomes often use different identifiers, formats and quality standards.
Statistical significance without biological context
Batch effects, population structure and confounders can look like meaningful biology.
No clear path from signal to measurement
A biomarker identified in research-grade data may not translate into a robust assay or practical clinical workflow.
Population-level findings, patient-level decisions
Cohort-average effects do not automatically support treatment response prediction or patient-level stratification.
Design biomarker discovery for replication from day one
Our approach treats AI biomarker discovery as a connected discovery and validation program. Replication is planned from the first cycle, not added after a candidate has already been selected. This makes data quality, cohort design and evidence traceability part of prioritization from the beginning.
Once the data is analysis-ready, biomarker identification becomes more than a discovery-cohort result. Each candidate can be evaluated across modalities, biological context and independent evidence, giving translational teams a stronger basis for the next decision.
Not sure whether your biomarker data is ready for AI?
Start by identifying integration gaps, missing cohort metadata and the evidence required for a credible validation plan.
How our AI biomarker discovery workflow works
Multimodal evidence integration
Harmonize relevant genomics, transcriptomics, proteomics, single-cell, imaging and clinical data with cohort metadata and endpoints in a reusable evidence base.
Biomarker identification with replication design
Detect candidate signals while explicitly modeling population structure, batch effects and confounders. Define discovery and validation cohorts before ranking the shortlist.
Biological and clinical context
Prioritize candidates using pathway evidence, cell-type specificity, treatment-effect plausibility and endpoint relevance, not a p-value alone.
Cross-cohort biomarker validation and translation planning
Test performance in independent data where available, document confidence and limitations, and connect the shortlist to assay feasibility and the next translational decision.
Where multiomics biomarker discovery supports your program
Patient stratification
Build biomarker-defined cohort hypotheses and patient-stratification criteria to inform downstream clinical trial design.
Predictive biomarkers and treatment response
Identify biomarker patterns associated with likely response or resistance and define how they should be tested in independent cohorts.
Pharmacodynamic and target engagement biomarkers
Connect candidate markers to mechanism, pathway activity and feasible measurement strategies.
Companion diagnostic strategy support
Evaluate discovery-stage candidates for measurement feasibility and evidence gaps that may affect a future diagnostic strategy.
What your team
receives
An analysis-ready evidence base that brings selected multiomics, clinical and cohort metadata into a governed structure.
A prioritized biomarker shortlist with the evidence, assumptions and uncertainty behind each candidate.
A cross-cohort validation plan that defines datasets, endpoints, covariates and decision criteria for the next stage.
Biological context summaries covering pathway, cell type, mechanism and endpoint relevance for leading candidates.
A reproducible computational workflow that can be rerun when new cohorts, modalities or evidence become available.
A clear handoff package for wet-lab assay development and clinical trial teams for prospective validation.
Why work with Ardigen
Computational depth with drug development context
Bioinformatics and AI are connected to the decisions your translational and clinical teams need to make.
Cross-cohort thinking from the start
Replication design is part of discovery rather than a separate final check.
Traceable prioritization
Your team can review the evidence, assumptions and limitations behind the ranking.
A flexible engagement model
Start with data readiness and feasibility, or engage Ardigen for an end-to-end computational biomarker discovery program.
Move from discovery-cohort signals to validation-ready biomarkers.
Bring us your data, candidate list or validation challenge. We will help define the evidence, analysis and next decisions needed to move forward.
Frequently Asked Questions
What data can be used for AI biomarker discovery?
The right inputs depend on the biological question and available cohorts. Relevant sources may include genomics, transcriptomics, proteomics, single-cell data, imaging, clinical outcomes and cohort metadata. We start by assessing data quality, identifiers, missingness, batch structure and endpoint availability.
Is this biomarker discovery, biomarker validation, or both?
We perform computational biomarker discovery paired with cross-cohort validation. Discovery and validation are designed together, with independent datasets and decision criteria defined as early as possible. Computational validation strengthens candidate evidence, providing a clear handoff for prospective wet-lab assay development and clinical trials.
How do you handle cohort heterogeneity, batch effects and population structure?
We model relevant cohort metadata, technical batches and population covariates during analysis. Candidate rankings are reviewed for sensitivity to those factors, and limitations are documented rather than hidden behind a single score.
Can you estimate biomarker performance before independent validation?
We can estimate expected performance within the limits of the available data using cross-validation, held-out cohorts and cross-modal corroboration where appropriate. The output includes assumptions and uncertainty, and independent validation remains necessary.
Is Ardigen Biomarkers a service or a software product?
This page describes Ardigen’s computational biomarker discovery services. Engagements are delivered as tailored Bio-ML service projects structured around your specific multiomics cohorts and translational goals.
Can the results support patient stratification or clinical development?
They can provide evidence and biomarker hypotheses for downstream patient stratification, cohort design and clinical trial design. The scope and handoff should be defined with the relevant translational and clinical stakeholders.
Build a biomarker strategy your team can defend
Start with the evidence you have and define what still needs validation
Contact
Start with clarity before you scale AI.
If your biomarker data is not structured for cross-cohort, multi-modal validation, adding models will not fix it. A short Biomarker data readiness assessment assessment shows exactly where the integration gaps are, what to fix first, and whether AI-driven biomarker discovery is the right next investment.
Send us a message and we will contact you back within 48 hours.
Newsletter
Become an insider
Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!